185 related articles for article (PubMed ID: 32182394)
1. A Tale of Two Trials.
Wofsy D
Arthritis Rheumatol; 2020 Aug; 72(8):1256-1257. PubMed ID: 32182394
[No Abstract] [Full Text] [Related]
2. What was wrong and might now go right with clinical trials for lupus?
Merrill JT
Curr Rheumatol Rep; 2009 Aug; 11(4):235-7. PubMed ID: 19691925
[No Abstract] [Full Text] [Related]
3. Anifrolumab (Saphnelo) for systemic lupus erythematosus.
Med Lett Drugs Ther; 2021 Sep; 63(1633):146-147. PubMed ID: 34550961
[No Abstract] [Full Text] [Related]
4. Reinventing clinical trials.
Allison M
Nat Biotechnol; 2012 Jan; 30(1):41-9. PubMed ID: 22231093
[No Abstract] [Full Text] [Related]
5. An overview of pharmacoepidemiology.
Wertheimer AL; Andrews KB
Pharm World Sci; 1995 May; 17(3):61-6. PubMed ID: 7550051
[TBL] [Abstract][Full Text] [Related]
6. Reslizumab: First Global Approval.
Markham A
Drugs; 2016 May; 76(8):907-11. PubMed ID: 27125787
[TBL] [Abstract][Full Text] [Related]
7. Approval on a knife edge.
Eisenstein M
Nat Biotechnol; 2012 Jan; 30(1):26-9. PubMed ID: 22231087
[No Abstract] [Full Text] [Related]
8. A critical review of clinical trials in systemic lupus erythematosus.
Mahieu MA; Strand V; Simon LS; Lipsky PE; Ramsey-Goldman R
Lupus; 2016 Sep; 25(10):1122-40. PubMed ID: 27497257
[TBL] [Abstract][Full Text] [Related]
9. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions.
Touma Z; Urowitz MB; Gladman DD
Expert Opin Biol Ther; 2013 May; 13(5):723-37. PubMed ID: 23339281
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars.
Edwards CJ; Bellinvia S
Lupus; 2020 May; 29(6):525-532. PubMed ID: 32188301
[No Abstract] [Full Text] [Related]
11. Examining heterogeneity in phase II trial designs may improve success in phase III.
Tuma RS
J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
[No Abstract] [Full Text] [Related]
12. String of successful trials in SLE: have we cracked the code?
van Vollenhoven R
Lupus Sci Med; 2020; 7(1):e000380. PubMed ID: 32095250
[No Abstract] [Full Text] [Related]
13. Drug development. Lupus drug company asks FDA for second chance.
Couzin J
Science; 2005 Feb; 307(5711):835. PubMed ID: 15705822
[No Abstract] [Full Text] [Related]
14. Landmark lupus approval opens door for next wave of drugs.
Nat Rev Drug Discov; 2011 Apr; 10(4):243-5. PubMed ID: 21455222
[No Abstract] [Full Text] [Related]
15. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Mosak J; Furie R
Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
[TBL] [Abstract][Full Text] [Related]
16. Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research.
J Immunother; 1997 May; 20(3):214-43. PubMed ID: 9181460
[No Abstract] [Full Text] [Related]
17. Ixekizumab: First Global Approval.
Markham A
Drugs; 2016 May; 76(8):901-5. PubMed ID: 27098317
[TBL] [Abstract][Full Text] [Related]
18. Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
Runkel L; Stacey J
Expert Opin Biol Ther; 2014 Apr; 14(4):491-501. PubMed ID: 24490627
[TBL] [Abstract][Full Text] [Related]
19. BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.
Fairfax K; Mackay IR; Mackay F
IUBMB Life; 2012 Jul; 64(7):595-602. PubMed ID: 22641424
[TBL] [Abstract][Full Text] [Related]
20. Interim analyses in clinical trials: why do we plan them?
Fossâ SD; Skovlund E
J Clin Oncol; 2000 Dec; 18(24):4007-8. PubMed ID: 11118460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
